Gentian violet study for painful skin condition pulled before it began
NCT ID NCT04388163
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study planned to test whether gentian violet, a common purple antiseptic, could reduce redness, drainage, and pain in people with hidradenitis suppurativa (HS). Participants would have applied the treatment once and returned a month later to report changes. However, the study was withdrawn before enrolling any volunteers, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- gentian violet (a topical antiseptic)
- What this could lead to
- If it had worked, this could have pointed toward a simple, low-cost topical option to ease symptoms of hidradenitis suppurativa.
- What could go wrong
- The study was withdrawn before enrolling anyone, so we have no data on whether gentian violet helps. Even if tested, results might not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Expected to start
-
Aug 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients must have active HS, be willing to undergo one application of HS, and agree to follow-up in one month. Exclusion Criteria: * Exclusion criteria include children, absent HS lesions at the time of clinic, and cognitive/physical impairments that would make them unable to assess quality of life factors of the survey.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wake Forest School of Medicine
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Weight-Loss drug also calm a painful skin disease?
- Viruses that kill bacteria: a new weapon against superbugs?
- Can an injected drug calm the painful flares of hidradenitis suppurativa?
- Nanobody drug tested against painful skin condition
- Can a mediterranean diet tame hidradenitis suppurativa?
- Can we predict the path of chronic skin disease?